CoChat

Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

Liu, Xu, Zhang, Yuan, Yang, Kun-Yu, Zhang, Ning, Jin, Feng, Zou, Guo-Rong, Zhu, Xiao-Dong, Xie, Fang-Yun, Liang, Xiao-Yu, Li, Wen-Fei, He, Zhen-Yu, Chen, Nian-Yong, Hu, Wei-Han, Wu, Hai-Jun, Shi, Mei, Zhou, Guan-Qun, Mao, Yan-Ping, Guo, Rui, Sun, Rui, Huang, Jing, Liang, Shao-Qiang, Wu, Wei-Li, Su, Zhen, Li, Ling, Ai, Ping, He, Yu-Xiang, Zang, Jian, Chen, Lei, Lin, Li, Huang, Shao Hui, Xu, Cheng, Lv, Jia-Wei, Li, Ying-Qing, Hong, Shu-Bin, Jie, Yu-Sheng, Li, Hao, Huang, Sai-Wei, Liang, Ye-Lin, Wang, Ya-Qin, Peng, Ying-Lin, Zhu, Jin-Han, Zang, Sheng-Bing, Liu, Song-Ran, Lin, Qing-Guang, Li, Hao-Jiang, Tian, Li, Liu, Li-Zhi, Zhao, Hong-Yun, Lin, Ai-Hua, Li, Ji-Bin, Liu, Na, Tang, Ling-Long, Chen, Yu-Pei, Sun, Ying, Ma, Jun · 2024 · The Lancet
Cited by 196

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains unknown in patients with locoregionally advanced nasopharyngeal carcinoma. We assessed the addition of sintilimab, a PD-1 inhibitor, to standard chemoradiotherapy in this patient population. METHODS This multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial was conducted at nine hospitals in China. Adults aged 18-65 years with newly diagnosed high-risk non-metastatic stage III-IVa locoregionally advanced nasopharyngeal carcinoma (excluding T3-4N0 and T3N1) were eligible. Patients were randomly assigned (1:1) using blocks of four to receive gemcitabine and cisplatin induction chemotherapy followed by concurrent cisplatin radiotherapy (standard therapy group) or standard therapy with 200 mg sintilimab intravenously once every 3 weeks for 12 cycles (comprising three induction, three concurrent, and six adjuvant cycles to radiotherapy; sintilimab group). The primary endpoint was event-free survival from randomisation to disease recurrence (locoregional or distant) or death from any cause in the intention-to-treat population. Secondary endpoints included adverse events. This trial is registered with ClinicalTrials.gov (NCT03700476) and is now completed; follow-up is ongoing. FINDINGS Between Dec 21, 2018, and March 31, 2020, 425 patients were enrolled and randomly assigned to the sintilimab (n=210) or standard therapy groups (n=215). At median follow-up of 41·9 months (IQR 38·0-44·8; 389 alive at primary data cutoff [Feb 28, 2023] and 366 [94%] had at least 36 months of follow-up), event-free survival was higher in the sintilimab group compared with the standard therapy group (36-month rates 86% [95% CI 81-90] vs 76% [70-81]; stratified hazard ratio 0·59 [0·38-0·92]; p=0·019). Grade 3-4 adverse events occurred in 155 (74%) in the sintilimab group versus 140 (65%) in the standard therapy group, with the most common being stomatitis (68 [33%] vs 64 [30%]), leukopenia (54 [26%] vs 48 [22%]), and neutropenia (50 [24%] vs 46 [21%]). Two (1%) patients died in the sintilimab group (both considered to be immune-related) and one (<1%) in the standard therapy group. Grade 3-4 immune-related adverse events occurred in 20 (10%) patients in the sintilimab group. INTERPRETATION Addition of sintilimab to chemoradiotherapy improved event-free survival, albeit with higher but manageable adverse events. Longer follow-up is necessary to determine whether this regimen can be considered as the standard of care for patients with high-risk locoregionally advanced nasopharyngeal carcinoma. FUNDING National Natural Science Foundation of China, Key-Area Research and Development Program of Guangdong Province, Natural Science Foundation of Guangdong Province, Overseas Expertise Introduction Project for Discipline Innovation, Guangzhou Municipal Health Commission, and Cancer Innovative Research Program of Sun Yat-sen University Cancer Center. TRANSLATION For the Chinese translation of the abstract see Supplementary Materials section.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00594-4

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Metadata

Authors
Liu, X., Zhang, Y., Yang, K.-Y., Zhang, N., Jin, F., Zou, G.-R., Zhu, X.-D., Xie, F.-Y., Liang, X.-Y., Li, W.-F., He, Z.-Y., Chen, N.-Y., Hu, W.-H., Wu, H.-J., Shi, M., Zhou, G.-Q., Mao, Y.-P., Guo, R., Sun, R., Huang, J., Liang, S.-Q., Wu, W.-L., Su, Z., Li, L., Ai, P., He, Y.-X., Zang, J., Chen, L., Lin, L., Huang, S. H., Xu, C., Lv, J.-W., Li, Y.-Q., Hong, S.-B., Jie, Y.-S., Li, H., Huang, S.-W., Liang, Y.-L., Wang, Y.-Q., Peng, Y.-L., Zhu, J.-H., Zang, S.-B., Liu, S.-R., Lin, Q.-G., Li, H.-J., Tian, L., Liu, L.-Z., Zhao, H.-Y., Lin, A.-H., Li, J.-B., Liu, N., Tang, L.-L., Chen, Y.-P., Sun, Y., & Ma, J.
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-06
Volume
403
Issue
10445
Pages
2720-2731
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4399163381
Cited by
196
References
6
FWCI
75.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00594-4
The paper
Liu, X., Zhang, Y., Yang, K.-Y., Zhang, N., Jin, F., Zou, G.-R., Zhu, X.-D., Xie, F.-Y., Liang, X.-Y., Li, W.-F., He, Z.-Y., Chen, N.-Y., Hu, W.-H., Wu, H.-J., Shi, M., Zhou, G.-Q., Mao, Y.-P., Guo, R., Sun, R., . . . Ma, J. (2024). Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(24)00594-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.